Nrc Health NRC
Biotechnology: Commercial Physical & Biological Resarch · data as of November 13, 2026
Nrc Health (NRC) is a healthcare company listed in the US with a market value of about $564M. In the twelve months to September 30, 2026 it had revenue of $144M and net income of $6M, a net margin of 4.3%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is track record (4/5); the weakest is future growth (0/5).
Key numbers: a P/E of 94.3, a price to free cash flow of 30.6, 5-year revenue growth of 1% a year, a 5-year average ROIC of 30%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 30% below the current price.
About Nrc Health
Nrc Health is listed in the US and classified in biotechnology: commercial physical & biological resarch. Revenue went from $99M in 2014 to $137M in 2025, growth of about 3.0% a year. It was profitable in 10 of the last 10 years in our data.
Score: 1.8 / 5
Checks passed
- PEG below 1.5
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Positive free cash flow
- Pays a dividend
- Dividend 3 years in a row
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $144M | $137M | $143M | $149M | $152M | $148M | $133M | $128M | $120M | $118M | $109M |
| Net income | $6M | $11M | $25M | $31M | $32M | $37M | $37M | $32M | $30M | $23M | $21M |
| Free cash flow | $18M | $16M | $19M | $22M | $26M | $41M | $37M | $36M | $34M | $24M | $23M |
| EPS (diluted) | $0.28 | $0.53 | $1.17 | $1.46 | $1.50 | $1.76 | $1.75 | $1.53 | $1.42 | $1.08 | $0.97 |
| Net margin | 4.3% | 8.2% | 17.3% | 20.8% | 21.0% | 25.3% | 27.9% | 25.3% | 25.1% | 19.5% | 18.8% |
| ROIC | — | 15.6% | 27.9% | 35.3% | 36.6% | 34.6% | 40.4% | 51.2% | 53.5% | 25.1% | 23.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $27.00, 2% above the current price; targets range from $27.00 to $27.00; the consensus rating is “none”; expected EPS is $0.39 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Nrc Health’s P/E ratio?
About 94.3, based on the last twelve months of diluted earnings per share (forward P/E about 26.6).
Is Nrc Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 30% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Nrc Health pay a dividend?
Yes. The dividend yield is about 2.41%, and it has paid dividends for 10 years in our data.
Is Nrc Health a good stock to buy?
We do not give buy or sell advice. Nrc Health scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.